PMDD vs. PMS: What’s the Difference?
PMS vs PMDD: Understanding the Differences, Diagnosis, and Treatment
Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are both tied to the menstrual cycle, yet they are very different in severity, diagnosis, and treatment. Many people live with premenstrual symptoms for years without knowing which they have, or that effective help exists.
This guide explains PMS vs PMDD: how each is defined, how PMDD is diagnosed under the DSM-5-TR, what research says about the biology, which treatments help, and how history and culture have shaped the way we talk about these conditions.
What Is Premenstrual Syndrome (PMS)?
PMS is a common group of physical and emotional symptoms that follow the menstrual cycle. Symptoms usually begin in the days to two weeks before a period and ease within a few days after it starts.
Common PMS symptoms include:
- Mood swings and irritability
- Breast tenderness and swelling
- Bloating and abdominal discomfort
- Fatigue and sleep changes
- Headaches
- Food cravings and appetite changes
- Mild anxiety or sadness
For most people, PMS is mild to moderate and does not seriously disrupt daily life. Most menstruating women notice at least some premenstrual symptoms during their reproductive years.
What Is Premenstrual Dysphoric Disorder (PMDD)?
PMDD is a severe, disabling form of premenstrual distress. Unlike PMS, it can seriously affect work, school, and relationships.
Key features of PMDD:
- Severe mood symptoms, including irritability, anger, anxiety, or deep sadness
- Marked depressive symptoms, such as hopelessness, and sometimes thoughts of suicide
- Physical symptoms like those of PMS, but more intense
- Clinically significant distress or impairment
- A cyclical pattern: symptoms worsen before the period and improve after it starts
The DSM-5 reports a 12-month prevalence of about 1.8% to 5.8% among women who menstruate. That makes PMDD less common than PMS, but its impact on mental health is greater.
DSM-5-TR Diagnostic Criteria for PMDD
The DSM-5-TR classifies PMDD as a depressive disorder. A diagnosis requires:
- Symptom number and type: at least five symptoms in the final week before menses, including at least one core mood symptom (mood swings, irritability or anger, depressed mood, or anxiety)
- Timing: symptoms begin in the luteal phase, improve within a few days after menses starts, and are minimal or absent in the week after
- Severity: symptoms cause significant distress or interfere with work, school, social life, or relationships
- Confirmation: daily symptom ratings tracked over at least two menstrual cycles, to rule out other conditions
PMS is not a DSM diagnosis. It is usually identified from symptom history, ideally with a symptom diary.
Why careful evaluation matters: many people with depression, anxiety, or other conditions notice their symptoms get worse before a period, which is called premenstrual exacerbation. It can look like PMDD, so a clinician needs to rule it out before diagnosing PMDD.
The Biology Behind PMS and PMDD
PMS and PMDD are not caused by abnormal hormone levels. Current research points instead to the brain’s increased sensitivity to normal hormonal changes, particularly progesterone and its metabolite allopregnanolone, which interacts with GABA receptors involved in mood and stress response.
Other contributing factors include:
- Serotonin signaling: helps explain why SSRIs work
- The stress response (HPA axis): may be disrupted in some people
- Genetics: PMDD runs in families, and twin and family studies suggest a substantial hereditary component
This understanding has opened the door to newer treatments that target brain chemistry and hormonal pathways.
PMS vs PMDD at a Glance
| PMS | PMDD | |
|---|---|---|
| Mood | Mild irritability, sadness, mood swings | Severe anger, anxiety, depression, rapid mood shifts |
| Physical | Bloating, fatigue, breast tenderness | Similar symptoms, but more intense and disabling |
| Impact | Temporary discomfort, mild interference | Major disruption to daily life |
| Diagnosis | Symptom history | DSM-5-TR criteria with daily symptom tracking |
Risk Factors and Triggers
Genetic and biological:
- A family history of PMS or PMDD
- A history of depression or anxiety
Environmental and lifestyle:
- Chronic stress or trauma
- Poor sleep
- Poor nutrition and little exercise
Evidence-Based Treatments
Managing PMS
- Lifestyle: regular exercise, stress management, yoga, and meditation
- Supplements: some people find calcium, magnesium, or vitamin B6 helpful. Evidence varies, with calcium the most consistent, and high doses of B6 can cause nerve problems, so check with a clinician first.
- Medication: NSAIDs for cramps and headaches
Treating PMDD
- SSRIs: the first-line treatment. They can be taken daily or only during the luteal phase, and they often work faster for PMDD than they do for depression.
- Cognitive behavioral therapy (CBT): builds mood regulation and coping skills
- Hormonal contraceptives: can reduce symptoms by suppressing ovulation, and drospirenone-containing pills have the best evidence
- GnRH agonists: reserved for severe, treatment-resistant cases, usually with add-back hormones under specialist care
- Emerging options: treatments that target neurosteroids are being studied
- Combination care: therapy, medication, and lifestyle support together often work best
Historical Perspectives
- Ancient Greece: medical writers blamed the uterus for many women’s physical and emotional complaints, an idea often summed up as the “wandering womb” and later called hysteria.
- 20th century: Robert Frank described “premenstrual tension” in 1931, and in 1953 Raymond Greene and Katharina Dalton popularized the term “premenstrual syndrome.”
- Modern psychiatry: PMDD appeared in the appendix of earlier DSM editions and became a full diagnosis in the DSM-5 (2013). The DSM-5-TR (2022) carries it forward as a depressive disorder, giving severe premenstrual mood symptoms formal recognition.
Cultural Perspectives
Attitudes toward menstrual symptoms vary widely. In some communities they’re discussed openly and treated as a normal part of life, while in others they are rarely mentioned. Western medicine tends to medicalize PMS and PMDD, which has sparked debate about the line between normal hormonal change and disorder. How people describe symptoms, whether emotional or physical, can also reflect cultural attitudes toward mental health. Access to care differs as well: herbal remedies are more common in some regions, and SSRIs and therapy in others. Stigma remains a barrier almost everywhere.
When to Seek Help
Reach out to a clinician if premenstrual symptoms disrupt your work, relationships, or daily life, or if you notice a pattern of severe mood changes before your period.
If you have thoughts of suicide, call or text 988, or go to the nearest emergency department. PMDD is associated with a higher risk of suicidal thoughts, and effective treatment is available.
Final Thoughts: A Holistic Approach
Understanding PMS and PMDD takes medical knowledge, cultural sensitivity, and compassion. The DSM-5-TR provides clarity, but each person’s experience is unique. If you or someone you know is struggling, treatment and support can make a real difference.
Meet Dr. My Phon Nguyen, M.D.
Dr. My Phon Nguyen specializes in evaluating and treating PMS and PMDD. She completed fellowship training in Women’s Mental Health and Reproductive Psychiatry at the University of Illinois at Chicago College of Medicine, the largest program of its kind in the U.S., under the mentorship of Dr. Marcela Almeida, M.D., who is now at Harvard Medical School’s Department of Psychiatry at Brigham and Women’s Hospital.
Dr. Nguyen combines the current DSM-5-TR criteria with an understanding of biological and cultural factors to provide personalized care through medication, psychotherapy, and lifestyle guidance.
Contact YOU Psychiatry Clinic
At YOU Psychiatry Clinic, we offer personalized, compassionate, and culturally respectful care. Learn more about our women’s mental health services, request an appointment in person or through telepsychiatry, or follow us on Instagram, TikTok, Facebook, and LinkedIn @youpsychiatryclinic for mental health education and to help destigmatize mental health.
– BE WELL, BE YOU ™
References
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
Baker, F. C., & Kronenberg, F. (2020). Premenstrual syndrome and premenstrual dysphoric disorder. In R. L. Nussbaum (Ed.), Women’s health and mental health (pp. 123–142). Springer.
Barry, J. A., Lawson, D. M., & King, S. (2019). Cross-cultural perspectives on premenstrual symptoms and disorders. International Journal of Women’s Health, 11, 281–291. https://doi.org/10.2147/IJWH.S176099
Borenstein, J., Dean, B., Endicott, J., Yonkers, K. A., & Pearlstein, T. (2022). Premenstrual dysphoric disorder: Evidence-based treatments and future directions. Journal of Women’s Health, 31(1), 12–20. https://doi.org/10.1089/jwh.2021.0195
Canguilhem, G. (1991). The normal and the pathological (C. R. Fawcett, Trans.). Zone Books. (Original work published 1943)
Dalton, K. (1953). Premenstrual syndrome: A biocyclic phenomenon in women. The Practitioner, 170(1023), 81–87.
Epperson, C. N., Steiner, M., & Hartlage, S. (2021). Premenstrual dysphoric disorder: Evidence for a neurobiological basis and treatment with serotonin reuptake inhibitors. Current Psychiatry Reports, 23(5), 30. https://doi.org/10.1007/s11920-021-01252-4
Huo, L., Korten, N. C. M., Toenders, Y. J., Bot, M., & Penninx, B. W. J. H. (2023). Genetic and environmental contributions to premenstrual dysphoric disorder. Psychological Medicine, 53(4), 633–640. https://doi.org/10.1017/S0033291722003016
Lowe, P. A., & Lee, S. H. (2021). Medicalization of premenstrual symptoms: A review of cultural and clinical perspectives. Culture, Medicine and Psychiatry, 45(2), 305–322. https://doi.org/10.1007/s11013-021-09704-8
Rapkin, A. J., & Akopians, A. (2021). Premenstrual syndrome and premenstrual dysphoric disorder: Evidence-based treatments. Obstetrics and Gynecology Clinics of North America, 48(4), 645–662. https://doi.org/10.1016/j.ogc.2021.08.003
Schmidt, P. J., Rubinow, D. R., & Roca, C. A. (2023). Neurosteroid modulation of GABA-A receptors in the treatment of PMDD. Neuropsychopharmacology Reviews, 48(1), 20–32. https://doi.org/10.1038/s41386-022-01450-9
Steiner, M., Pearlstein, T., Cohen, L. S., Endicott, J., Kornstein, S. G., Roberts, C., … & Yonkers, K. A. (2022). Premenstrual dysphoric disorder: Burden of illness and treatment update. Journal of Psychiatry & Neuroscience, 47(3), 159–171. https://doi.org/10.1503/jpn.210160
Yen, J. Y., Hu, H. F., Ko, C. H., Chang, Y. P., & Yen, C. F. (2017). Cross-cultural comparison of premenstrual symptoms in East Asian women: Emotional vs. physical symptom reporting. Archives of Women’s Mental Health, 20(4), 507–514. https://doi.org/10.1007/s00737-017-0703-3
